Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Jodi Holloway

Nurse Practitioner Newton, IA Nurse Practitioner

NPI 1013163427 CMS profile 10466245

300 N 4Th Ave E, Ste 200, Newton, IA 50208

Open in the dashboard

General payments

$2,818

218 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jodi Holloway of Newton, IA is reported in the CMS Open Payments database as having received $2,818 across 218 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 86th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $550 60
2024 General $629 51
2023 General $689 54
2022 General $589 30
2021 General $361 23

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jodi Holloway
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Jodi Holloway were reported at $550. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Jodi Holloway Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $361 $135 $40–$426 $132
2022 $589 $152 $48–$470 $149
2023 $689 $166 $54–$529 $160
2024 $629 $173 $55–$556 $164
2025 $550 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Pfizer Inc. $634 96 payments
  2. AbbVie, Inc. $348 20 payments
  3. Boehringer Ingelheim Pharmaceuticals, Inc. $228 12 payments
  4. Novo Nordisk Inc $202 10 payments
  5. Salix Pharmaceuticals, a division of Bausch Health US, LLC $179 10 payments
  6. Lilly USA, LLC $144 9 payments
  7. Bayer HealthCare Pharmaceuticals Inc. $134 7 payments
  8. Takeda Pharmaceuticals U.S.A., Inc. $114 6 payments
  9. Astellas Pharma US Inc $109 7 payments
  10. AstraZeneca Pharmaceuticals LP $106 7 payments
  11. Other $620 34 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $2,818 218 payments
Products named General payments · program years 2021–2025
  1. NURTEC ODT $504 88 payments
  2. ZAVZPRET $355 75 payments
  3. XIFAXAN $263 15 payments
  4. COMIRNATY $199 16 payments
  5. TRULANCE $179 10 payments
  6. VRAYLAR $163 8 payments
  7. Kerendia $134 7 payments
  8. PREVNAR 20 $118 7 payments
  9. PAXLOVID $114 11 payments
  10. JARDIANCE $109 6 payments
  11. Other $2,279 129 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 127 drugs

Part D claims

6,670

Median for Nurse Practitioner: 389

Drug cost

$581,930

Median for Nurse Practitioner: $21,885

Branded share of claims

22.7%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 106 $113,304
Ozempic Semaglutide Brand 60 $71,380
Jardiance Empagliflozin Brand 74 $68,720
Eliquis Apixaban Brand 54 $47,003
Rybelsus Semaglutide Brand 40 $44,067
Mounjaro Tirzepatide Brand 21 $22,295
Trulicity Dulaglutide Brand 13 $21,531
Januvia Sitagliptin Phosphate Brand 29 $21,503
Myrbetriq Mirabegron Brand 22 $20,845
Xarelto Rivaroxaban Brand 13 $20,448

The 10 drugs with the highest cost, of 127 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 96 billing codes

Paid by Medicare

$70,029

Of which drugs: $11,602

Medicare patients

208

Average age 74

Services billed

2,306

158 women, 50 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 71%
Arthritis 52%
Depression 31%
Diabetes 29%
Atrial fibrillation 18%
Chronic kidney disease 16%
Heart failure 15%
Osteoporosis 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Sarscov2 vac 50 mcg/0.5ml im 91322 Office 29 34 $5,027
Vaccine for influenza for injection into muscle 90662 Office 36 37 $2,709

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 22 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
NURTEC ODT
  • PFIZER INC. $92
$92 — —
ZAVZPRET
  • PFIZER INC. $75
$75 — —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $41
  • Lilly USA, LLC $16
$57 74 —
Wegovy
  • Novo Nordisk Inc $45
$45 — —
QULIPTA
  • AbbVie, Inc. $26
$26 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 22 in the dashboard with a free account

Records

218 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Iowa

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record